SANA Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

KUPNO 106141 min ago

@ $7.22

Wydano: 14 vas. 2024 @ 22:45

Zwrot: 20.86%

Poprzedni sygnał: vas. 13 - 21:34

Poprzedni sygnał: Sprzedaż

Zwrot: 12.56 %

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 23:00):

Stats
Dzisiejszy wolumen	1.59M
Średni wolumen	2.01M
Kapitalizacja rynkowa	1.92B
EPS	$0 ( 2024-03-21 )
Następna data zysków	( $-0.300 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-5.97
ATR14	$0.0150 (0.17%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-05	Bishop Hans Edgar	Buy	2 774	Common Stock
2024-04-01	Fmr Llc	Buy	0	Common Stock
2024-03-08	Yang Patrick Y	Sell	25 000	Common Stock
2024-03-07	Williams Douglas E	Buy	301 875	Stock Option (Right to Buy)
2024-03-07	Williams Douglas E	Buy	67 083	Restricted Stock Units

INSIDER POWER
6.23
Last 97 transactions
Buy: 15 455 910 \| Sell: 11 982 863

Wolumen Korelacja

Długi: -0.07 (neutral)

Krótki: -0.29 (neutral)

Signal:(47.218) Neutral

Sana Biotechnology, Inc. Korelacja

10 Najbardziej pozytywne korelacje
ALVR	0.839
MDVL	0.839
TCRT	0.836
USEG	0.834
HOOK	0.832
TLSA	0.832
GRAY	0.828
INFI	0.824
OPK	0.815
RUBY	0.815

10 Najbardziej negatywne korelacje
BNIXU	-0.875
MICT	-0.812

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Sana Biotechnology, Inc. Korelacja - Waluta/Towar

-0.34
( neutral )

-0.61
( weak negative )

0.00
( neutral )

-0.72
( moderate negative )

-0.18
( neutral )

-0.02
( neutral )

Sana Biotechnology, Inc. Finanse

Annual	2023
Przychody:	$0
Zysk brutto:	$-30.87M (0.00 %)
EPS:	$-1.460

FY	2023
Przychody:	$0
Zysk brutto:	$-30.87M (0.00 %)
EPS:	$-1.460

FY	2022
Przychody:	$0
Zysk brutto:	$-27.73M (0.00 %)
EPS:	$-1.410

FY	2021
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-1.958

Financial Reports:

No articles found.

Sana Biotechnology, Inc.

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is headquartered in Seattle, Washington.